Ai Feedback
Exact(10)
Since the presence of a BRCA1 or BRCA2 mutation status does not preclude the presence of additional susceptibility gene(s) which could contribute to disease penetrance, mutation positive patients were therefore not excluded from this analysis.
KRAS mutation status does not seem to represent a strong prognostic variable.
BRAF and NRAS mutation status does not influence survival in metastatic melanoma.
This suggests that mutation status does not consistently predict response to PF-03084014, in line with prior clinical trials.
Our results indicate that BRCA mutation status does not overtly impact PR-A and PR-B expression in the FTE.
Tumour mutation status does not seem to affect outcome from chemotherapy alone; however, its role has been only sparsely investigated.
Similar(50)
K-ras gene mutations were not detected in any of the EGFR mutated tumours and this negative correlation was statistically significant (P=0.001), while EGFR gene mutation status did not correlate with p53 gene mutation status or with promoter hypermethylation status of p16, RASSF1A, or APC1A gene (Table 4).
Interestingly, TP53 mutation status did not change during therapy in any of these patients (Supporting Information Table S1).
Although cell morphology changed over time, mutation status did not.
The VHL mutation status did not correlate to survival, TNM stage, or the Fuhrman grade.
In the BMS-099 trial, EGFR mutation status did not predict benefit from concurrent treatment with cetuximab and chemotherapy.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com